Jim Hill

Summary

Affiliation: Porton Down
Country: UK

Publications

  1. doi request reprint N255 is a key residue for recognition by a monoclonal antibody which protects against Yersinia pestis infection
    Jim Hill
    Defence Science and Technology Laboratory, Porton Down, Salisbury, Wiltshire SP4 0JQ, UK
    Vaccine 27:7073-9. 2009
  2. pmc Administration of antibody to the lung protects mice against pneumonic plague
    Jim Hill
    Defence Science and Technology Laboratory, Porton Down, Wiltshire SP4 OJQ, United Kingdom
    Infect Immun 74:3068-70. 2006
  3. pmc Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis
    Jim Hill
    Defence Science and Technology Laboratory, Porton Down, Wiltshire SP4 OJQ, United Kingdom
    Infect Immun 71:2234-8. 2003
  4. pmc A type IV pilin, PilA, Contributes To Adherence of Burkholderia pseudomallei and virulence in vivo
    Angela E Essex-Lopresti
    Dstl Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom
    Infect Immun 73:1260-4. 2005
  5. ncbi request reprint Identification of outer membrane proteins of Yersinia pestis through biotinylation
    Sophie J Smither
    Dstl, Porton Down, Room 201 Bldg 7a, Salisbury, Wilts, SP4 OJQ, UK
    J Microbiol Methods 68:26-31. 2007
  6. ncbi request reprint Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity
    Jim E Eyles
    Biomedical Sciences Department, Dstl, Porton Down, Wiltshire SP4 0JQ, UK
    Vaccine 25:7301-6. 2007
  7. doi request reprint Small protective fragments of the Yersinia pestis V antigen
    Claire Vernazza
    Defence Science and Technology Laboratory, Porton Down, Salisbury, Wiltshire, SP4 0JQ, UK
    Vaccine 27:2775-80. 2009
  8. ncbi request reprint Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis
    Mark P Stevens
    Division of Microbiology, Institute for Animal Health, Compton Laboratory, Berkshire RG20 7NN, UK
    Microbiology 150:2669-76. 2004
  9. ncbi request reprint The weak interaction of LcrV and TLR2 does not contribute to the virulence of Yersinia pestis
    Dagmar Reithmeier-Rost
    Max von Pettenkofer Institut fur Hygiene und Medizinische Mikrobiologie, Lehrstuhl Bakteriologie, Pettenkoferstrasse 9a, 80336 Munchen, Germany
    Microbes Infect 9:997-1002. 2007
  10. ncbi request reprint Interactions of the type III secretion pathway proteins LcrV and LcrG from Yersinia pestis are mediated by coiled-coil domains
    Daniel G Lawton
    Department of Biological Sciences, Centre for Molecular Microbiology and Infection, Flowers Building, Imperial College of Science, Technology and Medicine, London SW7 2AY, United Kingdom
    J Biol Chem 277:38714-22. 2002

Collaborators

Detail Information

Publications11

  1. doi request reprint N255 is a key residue for recognition by a monoclonal antibody which protects against Yersinia pestis infection
    Jim Hill
    Defence Science and Technology Laboratory, Porton Down, Salisbury, Wiltshire SP4 0JQ, UK
    Vaccine 27:7073-9. 2009
    ..3 protects by binding to LcrV(Ype) and interfering with protein-protein interactions necessary for type three secretion...
  2. pmc Administration of antibody to the lung protects mice against pneumonic plague
    Jim Hill
    Defence Science and Technology Laboratory, Porton Down, Wiltshire SP4 OJQ, United Kingdom
    Infect Immun 74:3068-70. 2006
    ..These data support the utility of inhaled antibodies as a fast-acting postexposure treatment for plague...
  3. pmc Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis
    Jim Hill
    Defence Science and Technology Laboratory, Porton Down, Wiltshire SP4 OJQ, United Kingdom
    Infect Immun 71:2234-8. 2003
    ..Antibodies showed synergy when administered prophylactically and as a therapy 48 h postinfection. Monoclonal antibodies therefore have potential as a treatment for plague...
  4. pmc A type IV pilin, PilA, Contributes To Adherence of Burkholderia pseudomallei and virulence in vivo
    Angela E Essex-Lopresti
    Dstl Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom
    Infect Immun 73:1260-4. 2005
    ..A pilA deletion mutant has reduced adherence to human epithelial cells and is less virulent in the nematode model of virulence and the murine model of melioidosis, suggesting a role for type IV pili in B. pseudomallei virulence...
  5. ncbi request reprint Identification of outer membrane proteins of Yersinia pestis through biotinylation
    Sophie J Smither
    Dstl, Porton Down, Room 201 Bldg 7a, Salisbury, Wilts, SP4 OJQ, UK
    J Microbiol Methods 68:26-31. 2007
    ..Tagged proteins were visualised through streptavidin probing of Western blots. Seven biotinylated proteins of Y. pestis were identified including two porins and the putative virulence factor catalase peroxidase...
  6. ncbi request reprint Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity
    Jim E Eyles
    Biomedical Sciences Department, Dstl, Porton Down, Wiltshire SP4 0JQ, UK
    Vaccine 25:7301-6. 2007
    ..pestis: intradermal injection might therefore be considered as a potential minimally invasive method of plague vaccine administration. These data have implications for the design of therapeutic strategies against plague infection...
  7. doi request reprint Small protective fragments of the Yersinia pestis V antigen
    Claire Vernazza
    Defence Science and Technology Laboratory, Porton Down, Salisbury, Wiltshire, SP4 0JQ, UK
    Vaccine 27:2775-80. 2009
    ..pestis in mice was determined. The smallest protective fragment of V antigen identified comprised amino acids 135-262. Finally the ability of this fragment to confer protection when given in the context of a DNA vaccine was confirmed...
  8. ncbi request reprint Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis
    Mark P Stevens
    Division of Microbiology, Institute for Animal Health, Compton Laboratory, Berkshire RG20 7NN, UK
    Microbiology 150:2669-76. 2004
    ..Mice inoculated with the B. pseudomallei bipD mutant were partially protected against subsequent challenge with wild-type B. pseudomallei. However, immunization of mice with purified BipD protein was not protective...
  9. ncbi request reprint The weak interaction of LcrV and TLR2 does not contribute to the virulence of Yersinia pestis
    Dagmar Reithmeier-Rost
    Max von Pettenkofer Institut fur Hygiene und Medizinische Mikrobiologie, Lehrstuhl Bakteriologie, Pettenkoferstrasse 9a, 80336 Munchen, Germany
    Microbes Infect 9:997-1002. 2007
    ..The low TLR2-activity of Y. pestis LcrV and associated cytokine expression might explain why - in contrast to Y. enterocolitica O:8 infection - TLR2-deficient mice are not more resistant than wild-type mice in a bubonic plague model...
  10. ncbi request reprint Interactions of the type III secretion pathway proteins LcrV and LcrG from Yersinia pestis are mediated by coiled-coil domains
    Daniel G Lawton
    Department of Biological Sciences, Centre for Molecular Microbiology and Infection, Flowers Building, Imperial College of Science, Technology and Medicine, London SW7 2AY, United Kingdom
    J Biol Chem 277:38714-22. 2002
    ....
  11. pmc A hypervariable N-terminal region of Yersinia LcrV determines Toll-like receptor 2-mediated IL-10 induction and mouse virulence
    Andreas Sing
    Lehrstuhl Bakteriologie, Max von Pettenkofer Institut fur Hygiene und Medizinische Mikrobiologie, Pettenkoferstrasse 9a, 80336 Munich, Germany
    Proc Natl Acad Sci U S A 102:16049-54. 2005
    ..LcrV is a defined bacterial virulence factor shown to target the TLR system for evasion of the host's immune response...